Research Topics

Michael F X Gnant

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. Gnant M, Mlineritsch B, Stoeger H, Luschin Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12:631-41 pubmed publisher
    ..These data show persistent benefits with zoledronic acid and support its addition to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer. AstraZeneca; Novartis. ..
  2. Gnant M, Pfeiler G, Dubsky P, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433-43 pubmed publisher
    ..Since a main side-effect of adjuvant breast cancer treatment can be substantially reduced by the addition of denosumab, this treatment should be considered for clinical practice. Amgen. ..
  3. Gnant M, Mlineritsch B, Schippinger W, Luschin Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-91 pubmed publisher
    ..The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer. (ClinicalTrials.gov number, NCT00295646.) ..
  4. Gnant M, Dubsky P, Hadji P. Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res. 2012;192:65-91 pubmed publisher
    ....
  5. Gnant M. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther. 2012;12:1579-89 pubmed publisher
    ..This article reviews the current data from studies of mTOR inhibitors everolimus and temsirolimus in combination with endocrine therapies to overcome treatment resistance in patients with advanced breast cancer. ..
  6. Gnant M, Pfeiler G, Stoger H, Mlineritsch B, Fitzal F, Balic M, et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer. 2013;109:589-96 pubmed publisher
    ..07). Body mass index may be used to predict outcome benefit of extended AI treatment in patients with receptor-positive breast cancer. ..

Locale

Detail Information

Publications6

  1. Gnant M, Mlineritsch B, Stoeger H, Luschin Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12:631-41 pubmed publisher
    ..These data show persistent benefits with zoledronic acid and support its addition to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer. AstraZeneca; Novartis. ..
  2. Gnant M, Pfeiler G, Dubsky P, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433-43 pubmed publisher
    ..Since a main side-effect of adjuvant breast cancer treatment can be substantially reduced by the addition of denosumab, this treatment should be considered for clinical practice. Amgen. ..
  3. Gnant M, Mlineritsch B, Schippinger W, Luschin Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-91 pubmed publisher
    ..The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer. (ClinicalTrials.gov number, NCT00295646.) ..
  4. Gnant M, Dubsky P, Hadji P. Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res. 2012;192:65-91 pubmed publisher
    ....
  5. Gnant M. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther. 2012;12:1579-89 pubmed publisher
    ..This article reviews the current data from studies of mTOR inhibitors everolimus and temsirolimus in combination with endocrine therapies to overcome treatment resistance in patients with advanced breast cancer. ..
  6. Gnant M, Pfeiler G, Stoger H, Mlineritsch B, Fitzal F, Balic M, et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer. 2013;109:589-96 pubmed publisher
    ..07). Body mass index may be used to predict outcome benefit of extended AI treatment in patients with receptor-positive breast cancer. ..